Christopher J. Lord

45.3k citations

192 papers · 24.5k indexed · 10 hit papers · h-index 68

Impact in

Oncology top 0.02%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Cancer Research top 0.2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 109
- PARP inhibition in cancer therapy 71
- Cancer-related Molecular Pathways 20
Molecular Biology 148
- DNA Repair Mechanisms 70
- CRISPR and Genetic Engineering 42
- Genomics and Chromatin Dynamics 11

Co-authors: Alan Ashworth Andrew Tutt Nuala McCabe Graeme C.M. Smith Niall M.B. Martin Stephen P. Jackson Hannah Farmer Damian A. Johnson
Journals: Cancer Research (14 papers)Oncogene (10 papers)The Journal of Pathology (9 papers)Molecular Cancer Therapeutics (7 papers)PLoS ONE (6 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Christopher J. Lord

191 papers receiving 24.2k citations

Hit Papers

10 papers align trajectories log scale

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer 2020 · 261 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Annals of Oncology
2019 Annals of Oncology
2018 Nature Reviews Clinical Oncology
2017 Science
2016 Nature reviews. Cancer
2016 Cancer Research
2012 Nature
2008 Nature
2006 Cancer Research
2005 Nature

Peers

Countries citing papers authored by Christopher J. Lord

Since Specialization

Citations

This map shows the geographic impact of Christopher J. Lord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Lord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Lord more than expected).

Fields of papers citing papers by Christopher J. Lord

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. Lord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Lord. The network helps show where Christopher J. Lord may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher J. Lord, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher J. Lord Line = papers co-authored together Christopher J. Lord links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin Nature Cell Biology ·Dragomir B. Krastev, Shudong Li, Yilun Sun, Andrew J. Wicks, J. Kaczmarek-Szewczyk, Daniel Weekes, Luned Badder, Eleanor Knight, Rebecca Marlow, Mercedes Pardo, Lu Yu, Tanaji T. Talele, Jiří Bártek, Jyoti S. Choudhary, Yves Pommier, Stephen J. Pettitt, Andrew Tutt, Kristijan Ramadan, Christopher J. Lord	2022	92
2	Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells PLoS Genetics ·Andrey A. Parkhitko, S. Protopopescu, Farjana Begum, Yanhui Hu, Richard Binari, Christopher J. Lord, Sridhar Hannenhalli, Colm J. Ryan, Norbert Perrimon	2021	7
3	Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance Cancer Discovery ·Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord	2020	114
4	Structural basis for allosteric PARP-1 retention on DNA breaks Science ·Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A. Hancock, Jamin D. Steffen, Ramya Billur, Zain M. Hannan, Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Christopher J. Lord, Tanaji T. Talele, John M. Pascal, Ben E. Black	2020	233
5	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer Molecular Cancer Therapeutics ·Kuban D. Naidoo, Patty T. Wai, Sarah Maguire, Frances Daley, Syed Haider, Divya Kriplani, James Campbell, Hasan Mirza, Anita Grigoriadis, Andrew Tutt, Paul M. Moseley, Tarek M.A. Abdel-Fatah, Stephen Chan, Srinivasan Madhusudan, qiankun Li, Ian O. Ellis, Christopher J. Lord, Yinyin Yuan, Andrew R. Green, Rachael Natrajan	2018	54
6	PARP inhibitors: Synthetic lethality in the clinic Science ·Christopher J. Lord, Alan Ashworth Hit paper breakdown →	2017	1876
7	Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers Molecular Cancer Therapeutics ·Amy Dréan, Chris T. Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac García-Murillas, Helen N. Pemberton, Jessica Frankum, Rumana Rafiq, Nicholas Badham, James Campbell, Aditi Gulati, Nicholas C. Turner, Stephen J. Pettitt, Alan Ashworth, Christopher J. Lord	2017	58
8	ATR Is a Therapeutic Target in Synovial Sarcoma Cancer Research ·Samuel E. Jones, Emmy D.G. Fleuren, Jessica Frankum, Asha Konde, Chris T. Williamson, Dragomir B. Krastev, Helen N. Pemberton, James Campbell, Aditi Gulati, Richard Elliott, Malini Menon, Joanna Selfe, Rachel Brough, Stephen J. Pettitt, Wojciech Niedźwiedź, Winette T.A. van der Graaf, Janet Shipley, Alan Ashworth, Christopher J. Lord	2017	47
9	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer Cancer Research ·María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A. Rivas, Rosalind Cutts, Isaac García-Murillas, Alex Pearson, Marta Guzmán, Olga Rodríguez, Judit Grueso, Meritxell Bellet, Javier Cortés, Richard Elliott, Sunil Pancholi, Christopher J. Lord, José Baselga, Mitch Dowsett, Lesley‐Ann Martin, Nicholas C. Turner, Violeta Serra Hit paper breakdown →	2016	511
10	Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways Molecular Cancer Therapeutics ·Marieke Aarts, Ilirjana Bajrami, María Teresa Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, Nicholas C. Turner	2015	48
11	An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor Cancer Discovery ·Nirupa Murugaesu, Marjan Iravani, Antoinette van Weverwijk, Aleksandar Ívetic, Damian A. Johnson, Aristotelis Antonopoulos, Antony Fearns, Mariam Jamal‐Hanjani, David Sims, Kerry Fenwick, Costas Mitsopoulos, Qiong Gao, Nick Orr, Marketa Zvelebil, Stuart M. Haslam, Anne Dell, Helen Yarwood, Christopher J. Lord, Alan Ashworth, Clare M. Isacke	2014	75
12	Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors Annual Review of Medicine ·Christopher J. Lord, Andrew Tutt, Alan Ashworth	2014	344
13	Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity Cancer Research ·Ilirjana Bajrami, Jessica Frankum, Asha Konde, Rowan Miller, Farah Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper, Lina Chen, Iwanka Kozarewa, Ioannis Assiotis, Kerry Fenwick, Rachael Natrajan, Christopher J. Lord, Alan Ashworth	2013	279
14	Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase Molecular Cancer Therapeutics ·壹岐伸弥, Mohamed A.M. El Gendy, Ana M. Mendes‐Pereira, Christopher J. Lord, Sunita Ghosh, Edan Foley, Alan Ashworth, Michael Weinfeld	2013	23
15	Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN Cancer Discovery ·Lynn Bjerke, Alan Mackay, Meera Nandhabalan, Anna Burford, Alexa Jury, Sergey Popov, Dorine A. Bax, Diana Carvalho, Kathryn R. Taylor, Maria Vinci, Ilirjana Bajrami, Imelda M. McGonnell, Christopher J. Lord, Rui Manuel Reis, Darren Hargrave, Alan Ashworth, Paul Workman, Chris Jones	2013	226
16	BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency Clinical Cancer Research ·Yuqiao Shen, Farah Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard Elliott, Bing Wang, Christopher J. Lord, Leonard Post, Alan Ashworth	2013	378
17	Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers Cancer Research ·Sarah A. Martin, Madeleine Hewish, David Sims, Christopher J. Lord, Alan Ashworth	2011	69
18	High-Throughput RNAi Screening Reveals Novel Regulators of Telomerase Cancer Research ·Maria Antonietta Cerone, Darren J. Burgess, Cristina Naceur‐Lombardelli, Christopher J. Lord, Alan Ashworth	2011	42
19	A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Clinical Cancer Research ·Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nick Orr, Marina Parton, Ian E. Smith, Jorge S. Reis‐Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner	2010	222
20	Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Cancer Research ·Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth Hit paper breakdown →	2006	977

About Christopher J. Lord

Christopher J. Lord is a scholar working on Oncology, Molecular Biology, Cancer Research, Genetics and Reproductive Medicine, having authored 192 papers that have together received 24.5k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (71 papers), DNA Repair Mechanisms (70 papers), CRISPR and Genetic Engineering (42 papers), Cancer Genomics and Diagnostics (22 papers), BRCA gene mutations in cancer (21 papers), Cancer-related Molecular Pathways (20 papers), Genomics and Chromatin Dynamics (11 papers) and Diabetes and associated disorders (10 papers). The work is most often cited by research in Oncology (15.1k citations), Cancer Research (4.1k citations), Molecular Biology (16.9k citations), Reproductive Medicine (1.9k citations) and Genetics (4.0k citations). Christopher J. Lord has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Alan Ashworth, Andrew Tutt, Nuala McCabe, Graeme C.M. Smith, Niall M.B. Martin, Stephen P. Jackson, Hannah Farmer, Damian A. Johnson, Ian Hickson and Charlotte Knights. Their work appears in journals such as Cancer Research, Oncogene, The Journal of Pathology, Molecular Cancer Therapeutics and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact